Category: Renal
Renal
NxStage Medical Inc. signed a five-year distribution deal with Nordic Medcomm AB to distribute its System One home hemodialysis system in Sweden, Denmark and Finland.
NxStage Medical Inc. (NSDQ:NXTM) inked a five-year deal with Nordic Medcom AB that will see the Swedish firm distribute NxStage's System One home hemodialysis system in Scandinavia.
Lawrence, Mass.-based NxStage said the terms of the deal includes the exclusive right for Nordic Medcomm to sell the home dialysis system and its PureFlow SL dialysate preparation system to dialysis centers in Sweden, Denmark and Finland. Nordic Medcomm can also choose to sell NxStage's Medisystems bloodlines and ButtonHole needles.
Spire Corp. is now mostly a clean energy company, after it closed the sale of its hemodialysis catheter business to C.R. Bard late last year for less than originally agreed.
Spire Corp. (NSDQ:SPIR) closed the sale of its hemodialysis catheter business to a division of C.R. Bard (NYSE:BCR) Dec. 16, after postponing the merger several times and agreeing to accept $2.5 million less than the original offer.
In September 2009, Spire agreed to sell the seven-year-old operation to the Salt Lake City-based device maker's Bard Access Systems division for $15 million, so it could focus on its core solar energy business.
NxStage Medical Inc. named John Mullen to lead its growth initiatives overseas.
NxStage Medical Inc. (NSDQ:NXTM) tapped John Mullen to fill its newly created international general manager position.
The Lawrence, Mass.-based home dialysis products maker said Mullen will be its vice president and general manager, international, charged with leading NxStage's growth initiatives overseas.
Spire Corp. and C.R. Bard agreed to postpone the $15 million buyout of Spire's hemodialysis catheter business for the third time, setting a new deadline for Dec. 11.
C.R. Bard (NYSE:BCR) has until the end of the week to consummate its $15 million deal for Spire Corp.'s (NSDQ:SPIR) hemodialysis catheter business — unless the companies decide to postpone the buyout for the fourth time.
A study showing patients using its home dialysis technology need less anti-hypertensive medications sends the Lawrence, Mass.-based hemodialysis firm's stock up nearly 5 percent.
Positive interim results from a study of NxStage Medical Inc.'s home dialysis technology sent the Lawrence, Mass.-based firm's stock soaring.
The hemodialysis device maker said interim results from its Freedom study show that patients performing daily home hemodialysis treatments needed significantly less anti-hypertensive medication than when they were treated at hemodialysis centers.
As of about 12:40 p.m. Oct. 27, NxStage stock was up 4.7 percent, trading at $5.97 per share.
The Natick, Mass.-based medical devices giant will distribute the Woburn firm's kidney stone treatment worldwide.
Boston Scientific Corp. spent an undisclosed amount for the worldwide distribution rights to Pluromed Inc.'s BackStop polymer gel plug for treating kidney stones.
